Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPROVE-2: Intermittent vs Continuous Panitumumab + FOLFIRI in mCRC
NCT06509126Phase 3Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2024
- Primary completion
- Jan 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of panitumumab in metastatic colorectal cancer (mCRC), sponsored by National Cancer Institute. Started Jun 2024; status: recruiting.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06509126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06509126.